Aktuellt
SENASTE
Fluoguide has progressed well clinically. Up next are regulatory talks about its glioblastoma ph3. We would like to get a closer look at the ph2b data, but at this point (admittedly on limited info) we identify no red flags. Photothermal therapy (PTT) will be accelerated, we believe, but the next step is a regulatory meeting on brain cancer. Cash is sufficient at least to mid-2024 and stretchable to 2025. We reiterate our equity valuation range of SEK 173-188 per share.
LÄS MER
